In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.
In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, breast cancer surgeon and partner at Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.
Transcript
Can you discuss the importance of investigating patient costs from breast cancer?
Breast cancer is actually the most expensive cancer that we treat in America. And as a breast cancer surgeon, I'm a fixer. I like to surgically resect tumors, and we fix the problem pretty quickly. So, one of the struggles that my patients have is cost of care, financial toxicity. I became very interested in this a couple years ago, because as a fixer, that is something we cannot quickly fix.
How does implementation of a value-based care model improve the quality of breast cancer treatments and patient outcomes?
A value-based care model, what it does is it really brings the patient forefront and center; it requires a collaborative approach. In the breast cancer world, this is typically done through a multidisciplinary tumor board. What we're looking at is specifically tailoring the therapy to the patient, appropriate care, appropriate surgery, [and] de-escalation of therapy when possible, which also eliminates both short-term and long-term side effects and financial repercussions.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More